70. Spinal stenosis Clinical trials / Disease details
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05029726 (ClinicalTrials.gov) | February 1, 2022 | 14/8/2021 | Regional Anesthesia in Minimally Invasive Lumbar Spine Surgery | Randomized, Placebo-controlled Trial of Erector Spinae Plane Blocks (ESPB) for Perioperative Pain Management for Minimally Invasive (MIS) Lumbar Spine Surgery | Lumbar Spinal Stenosis;Lumbar Disc Herniation;Lumbar Spondylolisthesis;Lumbar Spondylosis;Lumbar Radiculopathy;Lumbar Spine Instability;Synovial Cyst;Degenerative Disc Disease;Degenerative Spondylolisthesis;Degenerative Intervertebral Discs | Drug: Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine;Drug: normal saline | John O'Toole | NULL | Recruiting | 18 Years | 80 Years | All | 125 | Phase 4 | United States |
| 2 | EUCTR2019-003590-25-NL (EUCTR) | 15/06/2020 | 15/06/2020 | Epidural analgesia after back surgery | a Randomized controlled trial for epidural Analgesia for Pain relief after lumbar Interlaminar Decompressive spine surgery - RAPID - RAPID | Lumbar spinal stenosis MedDRA version: 21.0;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 100000004859;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml Product Name: Bupivacaine Product Code: Sufentanil | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 34 | Phase 4 | Netherlands | |||
| 3 | NCT04066296 (ClinicalTrials.gov) | September 8, 2019 | 3/7/2019 | Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine | A Double Blinded Randomized Control Trial in Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine | Lumbar Spinal Stenosis | Drug: Liposomal bupivacaine | University of Colorado, Denver | NULL | Recruiting | 18 Years | N/A | All | 100 | Phase 2 | United States |
| 4 | NCT03745040 (ClinicalTrials.gov) | January 26, 2019 | 5/11/2018 | Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion | Does Liposomal Bupivacaine Improve Postoperative Pain Control After One Level Posterior Spinal Fusion With Instrumentation | Lumbar Spinal Stenosis;Lumbar Disc Herniation;Lumbar Disc Disease;Lumbar Spondylolisthesis | Drug: Liposomal bupivacaine | Allina Health System | Twin Cities Spine Center | Recruiting | 18 Years | N/A | All | 60 | Phase 4 | United States |